Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study
F. Moik·J.M. Riedl·A. Amann·L. Weiss·R. Schaberl-Moser·H. Taghizadeh·M. Abdel Hamid·P. Reimann·A. Seeber·S.M. Kostmann·K.C. Zimmer·T. Winder·C. Bachleitner·R. Greil·P.J. Jost·L. Wagner·B. Doleschal·D. Wolf·F. Huemer·S.A. Suppe·H. Rumpold·A. Gerger
In this large real-world cohort of patients with mCRC, FTD-TPI + bevacizumab was associated with improved PFS and DCR compared with FTD-TPI or regorafenib, with consistent benefit across most molecular subgroups, including KRAS<sup>G12</sup> mutations.